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Introduction
In the clinical phase of drug development, it is important to 
establish appropriate endpoints. In general, to verify hard 
endpoints such as death, many subjects need to be studied 
over a long period of time, resulting in a large-scale clinical 
trial. To promote the early development of drugs, it is essen-
tial to establish methods for evaluating the clinical useful-
ness of treatment drugs by predicting long-term prognosis 
utilizing methods such as appropriate surrogate endpoints. 
In the field of nephrology, treatment of chronic diseases such 
as chronic kidney disease (CKD) and diabetic kidney disease 
(DKD) is not satisfactory, and demands for the development 
of new drugs are strong. In Europe and the US, the use of 
surrogate endpoints for such diseases is being debated.
Based on this situation, the “Research Working Group 
for Establishing Guidelines for Clinical Evaluation of CKD” 
was set up as a research funded by the Research on Regula-
tory Science of Pharmaceuticals and Medical Devices of 
the Japan Agency for Medical Research and Development 
(AMED). In this program, the Japanese Society of Nephrol-
ogy and Japanese Society of Diabetes worked together to 
establish guidelines for the clinical evaluation of treatment 
drugs for CKD, in collaboration with the Pharmaceuticals 
and Medical Devices Agency, analyzed data of Japanese 
cohorts. The aim of the project is to enable appropriate and 
prompt approval review of newly developed drugs without 
discrepancy from international criteria based on evidence 
for Japanese CKD patients.
In 2018, Japanese Society of Nephrology established the Research 
Working Group for Establishing Guidelines for Clinical Evaluation 
of CKD, which published “Guidelines for Clinical Evaluation of 
Chronic Kidney Disease” in the Japanese Journal of Nephrology, 
2018, vol. 60, issue 2, 67–100. This is the English version of that 
report. Chairman: Naoki Kashihara.
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In this study, we established the guidelines of appropri-
ate endpoints for the final evaluation of the effectiveness of 
newly developed drugs for CKD. In the study and develop-
ment of drugs, specific study designs and the selection of 
biomarkers as endpoints in Phase 2 studies are important, 
but these were not analyzed or reviewed in this study.
Preparation procedure
The progress of the establishment of this guideline is sum-
marized below. Throughout the whole program, discussions 
and exchange of opinions were frequently carried out by 
email. Related sessions were also set up during the various 
meetings of the Japanese Society of Nephrology to provide 
opportunities for the exchange of opinions.
Masaomi Nangaku participated in the KDIGO (Kidney 
Disease: Improving Global Outcomes) Controversies Con-
ference “Challenges in the Conduct of Clinical Trials in 
Nephrology” held in Paris, France, between September 8 
and 11, 2016, to gather information on international trends 
and exchange opinions.
The first working group meeting was held on September 
27, 2016. Prior to the meeting, preliminary discussions were 
carried out by email to verify planned analysis methods and 
role assignments of working group members. Thereafter, 
Eiichiro Kanda, Kunihiro Matsushita, and Tomoko Usui led 
a few analyses using data from Japanese studies such as a 
population-based cohort gathered by Kunitoshi Iseki and a 
Japanese CKD patient cohort study (CKD-JAC). In particu-
lar, the decline in estimate glomerular filtration rate (eGFR) 
and suitability of the surrogate endpoints of proteinuria/
albuminuria were reviewed. Furthermore, Eiichiro Kanda 
also conducted analysis of the Japanese DKD patient cohort 
study, as well as concurrently carried out systematic reviews 
of papers presented to date together with Tomoko Usui in 
a study led by Hirokazu Okada. Whether the results could 
be extrapolated to DKD was reviewed with the cooperation 
of Kohjiro Ueki, Hirotaka Watada, and Takashi Wada. The 
analytical work was overseen by Masaomi Nangaku, Naoki 
Kashihara, and Tetsuhiro Tanaka. Then, a rough draft of this 
guideline was prepared based on these analytical results with 
Kenichi Mikami, an open seminar was held on February 5, 
2017 to gather extensive views, and based on the results, 
the second working group meeting was held on the same 
day. Vlado Perkovic (Australia) and Prabir Roy-Chaudhury 
(USA) were invited to the seminar and working group meet-
ing as overseas experts to discuss differences from overseas 
trends. Based on the results of these meetings, the draft ver-
sion of this guideline was prepared, announced during the 
60th Annual Meeting of the Japanese Society of Nephrol-
ogy held between May 26 and 28, 2017, and discussed with 
participants. Then between August 2 and 14, 2017, public 
comments were gathered widely through the Japanese Soci-
ety of Nephrology and the Japan Diabetes Society, not lim-
ited to society members. The public comments received by 
email were then reviewed, and the third working group meet-
ing was held on October 8, 2017, to finalize the guideline.
Background
CKD is a serious problem worldwide [1]. The number of 
patients in Japan is estimated to be 13.3 million, making it 
a national disease [2]. To prevent CKD patients from reach-
ing end-stage renal disease (ESRD) which requires renal 
replacement therapy, there is a need to determine the pro-
gression factors of CKD, and establish treatment methods for 
protecting the kidneys. The development of treatments for 
CKD is an urgent task in terms of improving prognosis and 
Quality of Life of the patients, and from the perspective of 
economical healthcare. Also the development of treatments 
for DKD is particularly important, which is the number one 
cause for incipient dialysis. However, the development of 
treatments for CKD has been slow, and most treatments 
approved for CKD patients are targeting complications of 
CKD. In reality, the number of randomized control trials 
required for the approval of kidney disease treatments is very 
small compared to other areas [3]. The underlying reasons 
include absence of appropriate model animals due to the 
complicated pathophysiology of kidney disease and the dif-
ficulty of clinical trials [4].
To carry out appropriate clinical trials for CKD, it is 
essential to secure an adequate number of patients for out-
come evaluation, prevent dropouts during the trial period, 
and carry out correct statistical analysis using endpoints that 
are suitable for evaluation. In the clinical trials of drug effec-
tiveness evaluation of treatment drugs for CKD, hard end-
points such as renal death (dialysis or renal transplantation) 
or doubling of serum creatinine level have been used. To 
study this end point, there is a need to recruit many patients 
and follow up on them over a long time. This has made clini-
cal trials difficult.
In the clinical trials of CKD, the outcomes unique to kid-
ney are needless to say appropriate endpoints. Regarding 
setting mortality as an outcome, given that sensitivity and 
generalization feasibility are both low, it is rarely possible 
to appropriately use mortality as an endpoint of CKD clini-
cal trials [5]. Since deaths are caused by various reasons, 
it is hard to associate direct reasons with CKD studied in 
clinical trials. For CKD, ESRD has been used as the true 
endpoint in various clinical studies. The definition of ESRD 
differs according to the research. It often includes imple-
mentation of dialysis, renal transplantation, and doubling 
of serum creatinine level. However, given the low incidence 
rate of events, long-term observation and large-scale sample 
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size are required. For clinical studies to be carried out effi-
ciently, the development of useful surrogate endpoints is 
indispensable.
According to the US Biomarkers Definitions Working 
Group consisting mainly of members of the National Insti-
tutes of Health (NIH), a biomarker is defined as “a charac-
teristic that is objectively measured and evaluated as an indi-
cator of normal biological processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention.” 
[6], while a surrogate endpoint is defined as “a biomarker 
that is intended to substitute for a clinical endpoint. A sur-
rogate endpoint is expected to predict clinical benefit (or 
harm or lack of benefit or harm) based on epidemiologic, 
therapeutic, pathophysiologic, or other scientific evidence.” 
[6]. Consequently, surrogate endpoints are biomarkers and 
must be strongly associated with true endpoints.
The criteria for the strength of a surrogate endpoint are 
defined by the International Conference on Harmonization 
of Technical Requirements for Registration of Pharmaceuti-
cals for Human Use (ICH E9) as follows: (1) the biological 
plausibility of the relationship, (2) the demonstration in epi-
demiological studies of the prognostic value of the surrogate 
for the clinical outcome, and (3) evidence from clinical trials 
showing that treatment effects on the surrogate correspond 
to the effects on the clinical outcome [7].
If reliable surrogate endpoints are available, it may be 
possible to decrease the clinical study sample size and 
shorten the duration as well. Even for the evaluation of out-
comes specific to renal disease using surrogate endpoints, 
the appropriate endpoints are expected to vary according 
to the speed of progress and clinical stage of the disease. 
KDIGO proposed the endpoints shown in Table 1 based on 
the results of the controversy conference held in 2016 [5].
To optimize the design and operation of clinical trials, the 
international working group meeting hosted by the National 
Kidney Foundation (NKF) and Food and Drug Adminis-
tration (FDA) presented a series of papers reviewing the 
feasibility of using decrease in eGFR as surrogate endpoints 
of ESRD for clinical trials in 2014 [8–11]. The general 
conclusion of these papers supported 30–40% decrease in 
eGFR as a surrogate endpoint of ESRD [12]. This conclu-
sion was generally well received by researchers and drug 
regulatory authorities [13–15].
However, the papers of the NKF-FDA Working Group 
had a limitation of predominantly using research data from 
Europe and North America [8–11]. For instance, in a major 
paper from the Working Group using the data from the 
CKD Prognosis Consortium, only 0.5% of study population 
for ESRD were Asians [8]. Given the vast regional differ-
ences in the prevalence and incidence of ESRD (East Asian 
countries and regions such as Japan and Taiwan are ranked 
amongst the top in the world) [1, 16], as well as the fact 
that kidney disease pattern is unique in the Asian region 
(percentage of IgA nephropathy is relatively high, etc.) 
[17], the results from the NKF-FDA Working Group may 
not be simply extrapolated to Japanese. For Japanese CKD 
patients, a small study with 701 subjects demonstrated that 
a 30% decrease in eGFR over 2 years was strongly related to 
ESRD risk [18], but large-scale studies are needed for defi-
nite conclusions. As clinical trial endpoints, the decrease in 
albuminuria/proteinuria is frequently used, but the validity 
of surrogate endpoints replacing suppression of progress to 
ESRD has yet to be reviewed adequately.
Thus, in this study, the Chronic Kidney Disease Japan 
Cohort (CKD-JAC), a representative CKD cohort in 
Japan, and a health checkup database of Okinawa Pre-
fecture was analyzed in parallel. In addition, data from a 
randomized controlled trial (RCT) of Japanese patients 
with diabetic nephropathy were also analyzed. In addi-
tion, separate from the data analysis of these Japanese 
studies, systematic review on existing evidence was car-
ried out, and the results were also reviewed to establish 
this guideline. The results from the analysis of those stud-
ies indicated that it may not be optimal to apply a single 
surrogate outcome to any situations. Thus, this guideline 
tried to leave some flexibility. The appropriate number 
of measurements of serum creatinine level for calculat-
ing eGFR is not indicated in this guideline, since this 
Table 1  Renal disease endpoints proposed by KDIGO [5]
a For example, in patients with macroalbuminuria
b Surrogates may include measures of activity of disease (e.g., in lupus nephritis) or kidney structure (e.g., in adult polycystic kidney disease)
c The added value of eGFRs outside the routine study visit schedule has not yet been demonstrated and they may be unnecessary
CKD progressing slowly CKDa progressing fast
Early stage: CKD G1–G3a
(eGFR ≥ 45 ml/min per 1.73 m2)
Slope of mGFR or eGFR or surrogate  outcomeb or combinations of out-
comes
30–40% decline in eGFR using 
repeat measurements to rule 
out transient acute  effectsc
Late stage: CKD G3b–G5
(eGFR < 45 ml/min per 1.73 m2)
End-stage kidney disease or 30%~40% decline in  eGFRc End-stage kidney disease or 
doubling of serum creatinine 
level (or 40%~57% decline in 
eGFR)c
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cannot be calculated based on evidence. If we focus on 
a very specific population, it may be possible to make 
the descriptions more specific in this guideline. However, 
since it will not be possible to establish evidence due to 
the decrease in sample size to be reviewed in this case, 
the following descriptions were added. Given the possi-
bility that appropriate endpoints may differ according to 
the research, there is a need to set appropriate surrogate 
endpoints when designing studies, taking into account 
the characteristics of subjects, underlying disease, and 
test drug. DKD is an important cause of CKD. In Japan, 
DKD is the most common cause of incident dialysis since 
1998. In this study, it was specifically verified if surro-
gate endpoints can also be applied for DKD. For DKD, 
the management of blood glucose and blood pressure is 
obviously important [19]. There is a need to raise the 
awareness that even during the clinical trial of new drugs, 
their strict management is a major prerequisite.
Relation between decrease in estimated 
glomerular filtration rate in Japanese 




In this study, we investigated changes in eGFR and subse-
quent risk of ESRD using the data of the Chronic Kidney 
Disease Japan Cohort (CKD-JAC), a representative CKD 
cohort study in Japan. Details of the results of that cohort 
study were reported in a peer-reviewed journal, Kidney 
International (November 2016 issue). This section pro-
vides a key summary of that article [20].
The CKD-JAC was conducted to investigate risk fac-
tors for CKD progression in Japan, and its design and 
data gathering method have been presented in other 
papers [21, 22]. It included 2966 Japanese adults (age 
20–75 years with an eGFR of 10–59 ml/min/1.73 m2) 
from 17 clinical facilities throughout Japan from April 
2007 to December 2008 [22]. The following subjects were 
excluded: polycystic kidney disease, HIV infection, liver 
cirrhosis, organ transplantation, chronic dialysis, and 
pregnancy. At baseline, serum creatinine level, urinary 
albumin level, and medical history were investigated in 
addition to basic characteristics such as age. The patients 
with serum creatinine level within 1 year (2410 subjects) 
and 2 years (2079 subjects) measured at a central labora-
tory were enrolled in this analysis.
Change in eGFR
Serum creatinine level was measured at LSI Medience Cor-
poration (Tokyo, Japan) using an enzymatic method. The 
same machine and reagent were used for the measurements 
during the entire study period of the CKD-JAC. eGFR was 
calculated using an eGFR equation, which was developed by 
Matsuo and others, for the Japanese population [23]. Like 
the previous studies by the NKF-FDA Working Group, the 
changes in eGFR were calculated as follows:
(last eGFR at baseline period − first available eGFR)/(first 
available eGFR) × 100 [8, 10].
Although the NKF-FDA Working Group evaluated the 
changes in eGFR over 1–3 years, because the median fol-
low-up period of CKD-JAC was 3.9 years, the current study 
investigated the changes in eGFR over 1 and 2 years and the 
following risks of ESRD. The subsequent median follow-up 
period was 2.9 and 2.0 years, respectively.
ESRD (end‑stage renal disease)
The subjects were followed up every 6 months through 
clinical visits to the participating clinical facilities. Phone 
interviews were also carried out when needed. The primary 
endpoint was ESRD defined as the start of hemodialysis or 
peritoneal dialysis or kidney transplantation until March 31, 
2013. Subjects who did not develop ESRD were followed 
up until the last clinical visit, death, or March 31, 2013, 
whichever came first.
Covariates
Age, gender, and smoking status were based on informa-
tion reported by the subjects. Diabetes mellitus (DM) was 
defined as hemoglobin A1c ≧ 6.5%, history of diagnosis of 
DM, or use of glucose-lowering medications. A history of 
cardiovascular disease was defined as a history of coronary 
disease, stroke, or heart failure. A triple measurement aver-
age of blood pressure was analyzed. Serum total cholesterol 
level, hemoglobin level, urine albumin, and creatinine levels 
were measured at LSI Medience Corporation. Serum total 
cholesterol levels were measured using an enzymatic method 
and hemoglobin level by the SLS–Hb method. Urinary albu-
min and creatinine levels were measured with the trypsin 
inhibitor activity and enzymatic methods, respectively.
Statistical analysis
Baseline and clinical characteristics of the subjects were com-
pared between four groups of changes in eGFR [≦ − 53% (dou-
bling of serum creatinine level), > − 53 to − 30%, > − 30–0%, 
and > 0% (which is increase in eGFR)]. The Cox proportional 
hazards model was then used to estimate the adjusted hazard 
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ratios (aHRs) of ESRD to change in eGFR using spline terms 
with knots at − 53, − 25, − 10, 10, and 25%. In our primary 
analysis, such as the analysis done by the NKF-FDA Working 
Group, the Cox proportional hazards models were adjusted 
for age, gender, systolic blood pressure, serum total choles-
terol level, DM, history of cardiovascular disease, and first 
baseline eGFR. For sensitivity analysis, urinary albumin and 
hemoglobin levels were additionally included in the model. 
We also carried out analysis on subgroups by age, gender, and 
causes of CKD at baseline. Whether there were statistical inter-
actions was evaluated by comparing models with and without 
interactions between the subgroups and changes in eGFR using 
likelihood ratio tests. We also predicted the risks of ESRD by 
change in eGFR and baseline eGFR at 1–3 years after the base-
line period. At this time, other covariates were set as follows: 
age, 60 years; male, gender; systolic blood pressure, 130 mm 
Hg; serum total cholesterol level, 5 mmol/l; and no history of 
DM or cardiovascular disease. A competing risk model was 
used treating death as a competing endpoint.
Results
The characteristics of the subjects are summarized in 
Tables 2 and 3. Out of the 2410 subjects whose eGFR was 
measured 1 year later again after the baseline eGFR, 1.4% 
(34 subjects) showed more than 53% decrease. On the other 
hand, 4.3% (104 subjects) and 9.7% (233 subjects) showed 
changes in eGFR of more than 40% and more than 30%, 
respectively (Fig. 1a). And, 4.2% (87 subjects), 10.9% (227 
subjects), and 19.3% (401 subjects) of 2079 subjects showed 
more than 53, 40, and 30% decrease in eGFR over 2 years, 
respectively (Fig. 1b).
The average change in eGFR (SD) was − 13% (22%) over 
2 years and − 7% (19%) over 1 year. Compared to the group 
with moderate changes in eGFR (> − 30–0% change), those 
with more than 30% decrease in eGFR were mainly female, 
current smokers, and had a history of DM or cardiovascular 
disease. Moreover, many with 53–30% decrease in eGFR 
had high serum total cholesterol level, high blood pressure, 
high urinary albumin-to-creatinine ratio, low eGFR, and low 
hemoglobin level (Tables 2, 3).
Out of the 2410 participants reviewed for change in eGFR 
over 1 year and risk of ESRD, ESRD was observed in 498 
subjects (20.7%) during a median follow-up of 2.9 years. 
In the analysis of change in eGFR over 2 years, ESRD was 
observed 365 subjects (17.6%) out of 2079 subjects during 
a median follow-up of 2.0 years. The decrease in eGFR over 
1 and 2 years was strongly related to the risk of develop-
ing ESRD (Fig. 2). The relative risk of developing ESRD 
with the 53% decrease in eGFR over 1 and 2 years was 21- 
and 17-times (aHR 20.72 [95% confidence interval (CI), 
14.27–30.09] and 17.27 [11.80–25.30]), respectively. Both 
the 40 and 30% decreases in eGFR were also strongly related 
to ESRD risk. For the 1-year change, aHR was 9.61 (95% 
CI, 7.42–12.46) with the 40% decrease in eGFR and 5.32 
(4.14–6.85) with the 30% decrease in eGFR. For the 2-year 
change, it was 6.53 (4.70–9.05) with the 40% decrease in 
eGFR and 3.09 (2.15–4.42) with the 30% decrease in eGFR. 
Although increased risk of ESRD was associated with the 
increase in eGFR in the 1-year (Fig. 2a), the same tendency 
was not found in the 2-year analysis (Fig. 2b).
Following the analyses of the primary analysis, several 
sensitivity analyses were also examined. First, albumi-
nuria and hemoglobin levels were additionally adjusted, 
Table 2  Baseline characteristics of subjects with percentage change in eGFR over 1 year
Percentage change in eGFR over 1 year (%)
≤ − 53 > − 53 to ≤ − 30 > − 30 to ≤ 0 > 0
No. of subjects 34 199 1375 802
ESRD event, n (%) 30 (88.2) 133 (66.8) 256 (18.6) 79 (9.9)
Age, mean (SD), age 60.1 (11.8) 61.3 (11.4) 60.9 (11.5) 61.5 (11.1)
Female, n (%) 21 (61.8) 135 (67.8) 840 (61.1) 501 (62.5)
Smoker, n (%) 3 (8.8) 39 (19.6) 202 (14.7) 102 (12.7)
DM, n (%) 18 (52.9) 107 (53.8) 498 (36.2) 268 (33.4)
History of cardiovascular disease, n (%) 6 (17.6) 53 (26.6) 285 (20.7) 190 (23.7)
Total cholesterol, mean (SD), mmol/L 5.5 (1.8) 5.1 (1.3) 5 (1.1) 4.9 (1.1)
SBP, mean (SD), mmHg 140.1 (21.5) 138.1 (18.6) 132.1 (17.9) 127.6 (17.7)
DBP, mean (SD), mmHg 76.6 (10.2) 76.9 (12.3) 76.9 (12) 74.7 (11.5)
Use of antihypertensive drug, n (%) 34 (100) 197 (99) 1316 (95.7) 741 (92.4)
eGFR, mean (SD), ml/min/1.73 m2 22.3 (10.7) 20 (12.2) 28.2 (14.9) 28.5 (14.8)
Albuminuria, median (interquartile 
range), Alb mg/gCr
2663.3 (1205.5, 4070.9) 1688.7 (849.4, 3241.2) 627.4 (180.2, 1298.2) 186.7 (41.4, 559.5)
Hemoglobin, mean (SD), g/dL 10.5 (1.4) 11.1 (1.6) 12.2 (1.8) 12.2 (1.8)
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but similar results were obtained with regard to the rela-
tion between change in eGFR and ESRD risks (Fig. 3). 
Next, subgroup analyses were conducted by age, gender, 
and causes of CKD (diabetic nephropathy, hypertensive 
renal disease, glomerular disease, etc.) (Figs. 4, 5, 6). The 
association between change in eGFR and ESRD risk was 
found to be significantly stronger in men than in women 
(Interaction, P < 0.001, Fig. 5). Basically, the tendency for 
this strong association between change in eGFR and ESRD 
risk was the same in all the subgroups tested.
Finally, Figs. 7 and 8 summarize the results of predict-
ing eGFR at baseline and change in eGFR, and the risks of 
developing ESRD 1–3 years after the baseline period. When 
the baseline eGFR was 50 ml/min/1.73 m2 (CKD Stage 
G3a), the risk of ESRD in 3 years was predicted to be 4–5% 
even for the decrease in eGFR of 53% over 1 and 2 years. 
However, when baseline eGFR was 35 ml/min/1.73 m2 
(CKD Stage G3b), the risk was 35 and 30% for decrease 
in eGFR of 53% over 1 and 2 years, respectively. The risk 
was 19 and 11% for decrease in eGFR over 1 year and 14% 
and 7% for decrease in eGFR over 2 years of 40 and 30%, 
respectively. When baseline eGFR was 25 ml/min/1.73 m2 
(CKD Stage G4), the ESRD risk in 3 years was predicted to 
be 86, 61, and 42% for change in eGFR over 1 year of 53, 40 
and 30%, respectively (77, 45, and 26% for change in eGFR 
over 2 years of 53, 40 and 30%, respectively).
Table 3  Baseline characteristics of subjects with percentage change in eGFR over 2 years
Percentage change in eGFR over 2 years (%)
≤ − 53 > − 53 to ≤ − 30 > − 30 to ≤ 0 > 0
No. of subjects 87 314 1153 525
ESRD event, n (%) 71 (81.6) 154 (49) 104 (9) 36 (6.9)
Age, mean (SD), age 59.9 (10.6) 61.3 (11.6) 60.7 (11.2) 60.9 (11.4)
Female, n (%) 54 (62.1) 210 (66.9) 670 (58.1) 332 (63.2)
Smoker, n (%) 16 (18.4) 56 (17.8) 153 (13.3) 65 (12.4)
DM, n (%) 44 (50.6) 145 (46.2) 378 (32.8) 173 (33)
History of cardiovascular disease, n (%) 25 (28.7) 82 (26.1) 221 (19.2) 117 (22.3)
Total cholesterol, mean (SD), mmol/L 5.2 (1.4) 5.1 (1.1) 5 (1.1) 5 (1.1)
SBP, mean (SD), mmHg 137.8 (19.7) 136.5 (16.5) 130.5 (17.3) 125.5 (17.8)
DBP, mean (SD), mmHg 76.7 (12.2) 77.3 (12) 76.5 (11.4) 74.4 (11.9)
Use of antihypertensive drug, n (%) 86 (98.9) 312 (99.4) 1092 (94.7) 481 (91.6)
eGFR, mean (SD), ml/min/1.73 m2 24.4 (11.1) 22.2 (11.2) 30 (14.9) 30 (15)
Albumin-to-creatinine ratio, median (inter-
quartile range), mg/g
1602.8 (956.7, 3262.3) 1292.4 (604, 2291.6) 482.1 (130.1, 1049.8) 128.3 (29.9, 408.9)
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Fig. 1  Distribution of percentage changes in eGFR. a Percentage change in eGFR over 1 year. b Percentage change in eGFR over 2 years. Per-
centage change in eGFR was calculated as follows: (last eGFR at baseline period − first available eGFR)/(first available eGFR) × 100
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Discussion
In this study, changes in eGFR over 1 and 2 years were con-
firmed to be strongly associated with subsequent ESRD risk 
in Japanese CKD patients regardless of adjustments for con-
founders and baseline eGFR. Given the fact that doubling 
of serum creatinine level has already been accepted as a 
surrogate endpoint of ESRD, 53% decrease in eGFR over 
1 and 2 years showed 17–21 times higher risk of ESRD 
than 0% change in eGFR. Although not as high as the 53% 
decrease, 40 and 30% decrease in eGFR over 1 and 2 years 
led to significantly high risk of ESRD (7–10 times and 3–5 
times, respectively). Since 30% decrease in eGFR or greater 
was found in five to seven times more subjects compared to 
53% decline, this is an important finding when the number 
of events and statistical power are estimated in the clinical 
trials. Basically, the decrease in eGFR was related to the 
increase in ESRD regardless of age, gender, and causes of 
CKD.
In this analysis, although the association between 
decrease in eGFR and ESRD risk was found to be contin-
uous in our study (Fig. 2), it is not easy to narrow down 
thresholds for decrease in eGFR to a surrogate endpoint. 
Bringing the threshold for decrease in eGFR closer to the 
doubling of serum creatinine level leads to the identification 
of cases with very high ESRD risk, but the number of events 
will be limited. On the other hand, selecting a more moder-
ate decrease in eGFR as the threshold enables more cases to 
Fig. 2  Relationships between percentage changes in eGFR and risk 
of ESRD. a Percentage change in eGFR over 1  year. b Percentage 
change in eGFR over 2 years. The hazard ratio of ESRD according to 
percentage change in eGFR was adjusted for age, gender, DM, history 
of cardiovascular disease, systolic blood pressure, serum total choles-
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Fig. 3  Relationships between percentage changes in eGFR and risk 
of ESRD. a Percentage change in eGFR over 1  year. b Percentage 
change in eGFR over 2 years. The hazard ratio of ESRD according to 
percentage change in eGFR was adjusted for age, gender, DM, history 
of cardiovascular disease, systolic blood pressure, serum total choles-
terol level, and first available eGFR, as well as urinary albumin-to-
creatinine ratio and hemoglobin levels
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be taken as events, but this means that cases with relatively 
low ESRD risk will also be included in the events. How-
ever, 30–40% decrease in eGFR was proposed as a surrogate 
endpoint of CKD progression by the NKF–FDA Working 
Group, based on assessment of the relation between change 
in eGFR and ESRD risk, differences in the evaluation of 
treatment results using ESRD and surrogate endpoints, and 
numerous simulation analyses, and this is an important fact. 
Where there are no acute effects of new drugs on eGFR or 
small protective effects in the subjects with GFR less than 
30 ml/min/1.73 m2, 30% decrease in eGFR was proposed as 
an appropriate surrogate endpoint by the NKF–FDA Work-
ing Group [12]. For drugs whose positive acute effects 
continue over a long term, the use of change in eGFR of 
more than 30% as a surrogate endpoint is also evaluated as 
suitable. The group also stated that the surrogate endpoint 
of 40% is adequate for a wide range of acute effects and 
baseline eGFRs [8]. The threshold for surrogate endpoints 
cannot be determined from our study alone, but our results 
and the statement of the group suggest that more moderate 
decrease in eGFR than 53% may be an appropriate surrogate 
endpoint of CKD progression in Japanese CKD patients.
In this study, decrease in eGFR was found to be strongly 
related to ESRD risk statistically in men than in women. 
This result may be consistent with previous studies showing 
that GFR decline in men is faster than in women [24, 25]. 
However, controversy surrounds this issue of the relation 
of gender difference to the decrease in GFR [26]. Still, it 
is an important fact that the decrease in eGFR and ESRD 
risk was found to be consistently associated in both men 
and women. Consistent association was more or less found 
across subgroups by age and causes of CKD including dia-
betic nephropathy. Given that DM is the leading cause of 
ESRD in developed countries and is an important disease 
Fig. 4  Relationships between percentage changes in eGFR and risk of 
ESRD by age. a Percentage change in eGFR over 1  year (less than 
65 years old). b Percentage change in eGFR over 2 years (less than 
65 years old). c Percentage change in eGFR over 1 year (65 years old 
or older). d Percentage change in eGFR over 2  years (65 years old 
or older). The hazard ratio of ESRD according to percentage change 
in eGFR was adjusted for age, gender, DM, history of cardiovascu-
lar disease, systolic blood pressure, serum total cholesterol level, and 
first available eGFR
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for designing and executing clinical trials, this finding is 
considered significant.
Although the main objective of this study was to evalu-
ate the effects of change in eGFR on prognosis, a relation 
between an increase in change in eGFR over 1 year and 
increase in ESRD risk was observed. In the meta-analysis 
of the NKF–FDA Working Group, the relation between an 
increase in eGFR and risk of death was observed, but no 
association was seen for ESRD risk [8]. Past studies have, 
however, reported this association between increase in eGFR 
and ESRD risk [27, 28]. Several mechanisms have been pro-
posed for the reasons why the increase in eGFR increases 
ESRD risk. For example, patients recovering from acute kid-
ney injury may have shown increased eGFR. An increase in 
eGFR (decrease in serum creatinine level) may suggest loss 
of muscle mass or volume overload [8, 29]. However, this 
increase in eGFR over 2 years was not necessarily associ-
ated with an increase in ESRD risk in this study, thus the 
association between an increase in eGFR and ESRD risk is 
not fully clarified at this stage.
The results of this study may extend beyond Japanese CKD 
patients, and it may be possible to generalize our findings to 
other East Asian countries or regions according to relatively 
similar lifestyles (high sodium intake, etc.) and risks of ESRD 
and cardiovascular events [30, 31]. In addition, because the 
meta-analyses of the NKF-FDA Working Group coincided 
with the results of the relation between change in eGFR and 
risk of ESRD in our study, it was suggested that universal 
surrogate endpoints can be used in joint international trials.
There are several limitations in this study. First, due to the 
comparatively short follow-up time, this disabled the evalua-
tion of changes in eGFR over 3 years. In this study, the relative 
risk of changes in eGFR over 2 years was weaker than that over 
1 year, and this may be due to the short follow-up. Second, 
given that there was no information on events after onset of 
ESRD, we could not evaluate the relation between changes 
Fig. 5  Relationships between percentage changes in eGFR and risk of 
ESRD by gender. a Percentage change in eGFR over 1 year (male). b 
Percentage change in eGFR over 2 years (male). c Percentage change 
in eGFR over 1  year (female). d Percentage change in eGFR over 
2 years (female). The hazard ratio of ESRD according to percentage 
change in eGFR was adjusted for age, gender, DM, history of car-
diovascular disease, systolic blood pressure, serum total cholesterol 
level, and first available eGFR
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in eGFR and mortality. However, since there were records 
on deaths prior to ESRD, it was possible to review compet-
ing risks due to all deaths. Finally, although the possibility of 
threats of external validity of this study is low, we think that 
it is important to verify the relation between the decrease in 
eGFR and ESRD risk in other Asian countries and regions.
Conclusion
Association was confirmed between changes in eGFR less 
than the doubling of serum creatinine level and the risk of 
ESRD in Japanese CKD patients. This association was con-
sistent in subgroups by causes of CKD including diabetic 
Fig. 6  Relationships between 
percentage changes in eGFR 
and risk of ESRD by causes of 
nephropathy. Percentage change 
in eGFR over 1 year. a Diabetic 
nephropathy; b hypertensive 
nephropathy; c glomerular 
disease; d others. Percentage 
change in eGFR over 2 years. 
e Diabetic nephropathy; f hyper-
tensive nephropathy; g glo-
merular disease; h others. The 
hazard ratio of ESRD according 
to percentage change in eGFR 
was adjusted for age, gender, 
DM, history of cardiovascular 
disease, systolic blood pressure, 
serum total cholesterol level, 
and first available eGFR
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-53 -40 -30 -25 -20 -10 0 10 25
1 61 (45, 74) 37 (28, 45) 23 (18, 30) 18 (14, 24) 13 (10, 17) 6.8 (5.2, 9.4) 5 (3.7, 6.7) 3.7 (2.2, 6.2) 9.6 (5.6, 19)
2 90 (79, 96) 67 (57, 78) 47 (39, 58) 38 (30, 49) 29 (23, 36) 16 (13, 21) 12 (8.9, 15) 8.8 (5.2, 13) 22 (14, 39)
3 98 (94, 100) 87 (79, 94) 69 (58, 79) 58 (48, 72) 46 (39, 56) 27 (22, 34) 20 (16, 25) 15 (9.8, 24) 36 (23, 58)
1 36 (24, 49) 19 (14, 26) 12 (8.7, 16) 8.9 (6.6, 13) 6.4 (4.9, 8.7) 3.2 (2.4, 4.3) 2.4 (1.7, 3.1) 1.8 (1, 2.9) 4.7 (2.7, 9.2)
2 66 (49, 81) 41 (31, 51) 26 (20, 35) 20 (15, 28) 15 (11, 19) 7.8 (6, 10) 5.7 (4, 7.4) 4.2 (2.5, 6.7) 11 (6.8, 21)
3 86 (71, 95) 61 (49, 74) 42 (33, 56) 34 (26, 47) 25 (20, 34) 14 (10, 18) 10 (7.3, 13) 7.5 (4.5, 12) 19 (12, 33)
1 19 (11, 27) 9.6 (6.4, 14) 5.6 (3.9, 8.3) 4.3 (3, 6.4) 3.1 (2.2, 4.6) 1.5 (1.1, 2.6) 1.1 (.76, 1.6) .83 (.46, 1.5) 2.2 (1.2, 4.2)
2 40 (25, 55) 22 (15, 30) 13 (9.4, 18) 10 (7.1, 15) 7.3 (5.3, 9.9) 3.7 (2.7, 5.2) 2.7 (1.8, 3.6) 2 (1.2, 3.4) 5.3 (3.1, 10)
3 60 (41, 77) 36 (24, 48) 23 (16, 32) 18 (13, 26) 13 (9.4, 18) 6.7 (4.9, 9.2) 4.9 (3.4, 6.7) 3.6 (2.1, 6.2) 9.5 (5.6, 17)
1 9.4 (4.9, 15) 4.7 (2.8, 7.2) 2.7 (1.8, 4.2) 2 (1.3, 3.3) 1.5 (1, 2.4) .73 (.49, 1.3) .54 (.32, .79) .39 (.2, .75) 1.1 (.56, 2.2)
2 21 (12, 33) 11 (6.6, 17) 6.5 (4.2, 9.8) 4.9 (3.2, 7.4) 3.5 (2.4, 5.6) 1.8 (1.2, 3) 1.3 (.8, 1.8) .96 (.51, 1.7) 2.6 (1.5, 5.1)
3 35 (21, 52) 19 (11, 28) 11 (7.6, 18) 8.8 (5.7, 14) 6.3 (4.4, 9.2) 3.2 (2.2, 4.8) 2.4 (1.4, 3.5) 1.7 (.94, 3) 4.6 (2.5, 8.4)
1 4.5 (2.3, 8.1) 2.2 (1.2, 3.8) 1.3 (.78, 2.4) .97 (.6, 1.9) .69 (.44, 1.2) .35 (.22, .67) .25 (.14, .42) .18 (.09, .38) .5 (.26, 1.1)
2 11 (5.4, 18) 5.3 (3, 8.7) 3.1 (1.9, 4.9) 2.4 (1.4, 3.8) 1.7 (1.1, 2.9) .84 (.54, 1.5) .62 (.34, .94) .45 (.22, .82) 1.2 (.63, 2.4)
3 19 (10, 30) 9.5 (5, 15) 5.6 (3.3, 8.8) 4.2 (2.5, 7.1) 3 (1.9, 4.7) 1.5 (.97, 2.6) 1.1 (.63, 1.8) .82 (.4, 1.5) 2.2 (1.2, 4.1)
1 2.2 (1, 4.2) 1.1 (.55, 2) .61 (.34, 1.2) .46 (.26, .96) .33 (.2, .6) .16 (.1, .34) .12 (.061, .22) .087 (.038, .17) .24 (.11, .5)
2 5.2 (2.4, 9.6) 2.6 (1.3, 4.5) 1.5 (.82, 2.6) 1.1 (.64, 2.3) .79 (.48, 1.4) .4 (.24, .78) .29 (.15, .48) .21 (.093, .41) .57 (.29, 1.2)
3 9.2 (4.2, 16) 4.6 (2.3, 7.8) 2.7 (1.5, 4.5) 2 (1.1, 3.6) 1.4 (.84, 2.6) .72 (.43, 1.4) .53 (.29, .92) .39 (.17, .76) 1 (.52, 2)
1 1 (.41, 2.2) .5 (.24, 1) .29 (.15, .61) .22 (.12, .49) .15 (.084, .3) .077 (.043, .17) .056 (.027, .11) .041 (.016, .087) .11 (.05, .24)
2 2.5 (1.1, 5.2) 1.2 (.58, 2.4) .7 (.36, 1.3) .53 (.27, 1) .37 (.21, .73) .19 (.1, .4) .14 (.065, .25) .1 (.041, .2) .27 (.13, .6)











Change in eGFR1 During 1-Year Baseline Period, %
20
25
Color scale based on predicted risks 
Fig. 7  Predicted risk of ESRD and change in eGFR over 1  year. 
Values are estimated 1- to 3-year risk of ESRD (%) with 95% con-
fidence interval. Other covariates were set as follows: age, 60 years; 
gender, male; systolic blood pressure, 130 mm Hg; total cholesterol 
level, 5  mmol/l; and no history of DM or cardiovascular disease. 
Competing risk model was examined taking all-cause mortality as 
the competing endpoint. Serum total cholesterol level of 1 mmol/l is 
38.67 mg/dL
Fig. 8  Predicted risk of ESRD and change in eGFR over 2 years. 
Values are estimated 1- to 3-year risk of ESRD (%) with 95% con-
fidence interval. Other covariates were set as follows: age, 60 years; 
gender, male; systolic blood pressure, 130 mm Hg; total cholesterol 
level, 5  mmol/l; and no history of DM or cardiovascular disease. 
Competing risk model was examined taking all-cause mortality as 
the competing endpoint. Serum total cholesterol level of 1 mmol/l is 
38.67 mg/dL
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nephropathy and age. The NKF–FDA Working Group rec-
ommends the use of more than 40% decrease in eGFR as 
a surrogate endpoint to various situations and more than 
30% decrease to limited situations (e.g., no acute effects of 
drugs). The results of this study indicate that this approach 
is reasonable even in Japanese CKD patients.
Assessment of percentage change in eGFR 
as surrogate endpoint for end‑stage renal 
disease: analysis of data of general health 




Data The data of 69,727 subjects who were screened in 
health examinations by the Okinawa General Health Main-
tenance Association (OGHMA) from 1993 to 1996 were 
used in this study [32]. Of this, the data of 69,238 subjects 
without missing values in the baseline data at the start of 
the study were analyzed. Serum creatinine levels at the last 
eGFR at the baseline period were not imputed. Taking the 
development of ESRD (initiation of dialysis) to be the end-
point, 15-year follow-up survey was conducted. No data 
on deaths were obtained. As serum creatinine levels were 
measured using the Jaffe reaction, they were converted so 
that they conformed to enzymatic method levels [32]. eGFR 
was calculated using the equation developed by Japanese 
Society of Nephrology [23]:
note: 0.739 times in the case of female. Cr is serum creati-
nine level (mg/dl).
Percentage changes in eGFR were calculated using the 
following equation [8]:
note: First available eGFR and last eGFR at baseline period 
indicate the first available eGFR and last eGFR. The obser-
vational period was 1–3 years.
eGFR (ml∕min∕1.73 m2) = 194 × Cr−1.094 × age−0.287,
Percentage changes in eGFR (%∕observational period)
=
(last eGFR at baseline period − first available eGFR)
first available eGFR
× 100.
Statistical analyses Subjects with eGFR 60 ml/min/1.73 m2 
or more at the start of the study were defined as the high-
eGFR group and those with eGFR 60 ml/min/1.73 m2 or 
less as the low-eGFR group. Percentage change in eGFR 
every 10% was set as the cutoff level [8]. The relationship 
between the percentage change in eGFR and the time to 
ESRD onset was evaluated using the Cox proportional haz-
ards model. With this model, percentage changes in eGFR 
were used as continuous variables, and adjustments were 
made with baseline characteristics such as gender, age, 
body mass index (BMI), systolic blood pressure, serum 
total cholesterol level, eGFR, and urinary protein level 
(dipstick). aHRs and 95% CIs were acquired using spline 
curves. Next, the positive predictive value (PPV) of ESRD 
onset for each cutoff level was calculated taking sensitivity 
and specificity to be fixed values, and assuming prevalence 
to vary:
Details of the study results have been reported in “Clini-
cal and Experimental Nephrology”. An outline is provided 
below [33].
Results
The characteristics of each group are summarized in 
Table 4. The distributions of percentage changes in eGFR 
are shown in Fig. 9. The high-eGFR group consisted of 
58,292 subjects, and data on percentage changes in eGFR 
over 1–3 years were obtained from 47,688 subjects, 43,381 
subjects, and 42,061 subjects, respectively. The low-eGFR 
group consisted of 10,946 subjects, and data on percentage 
changes in eGFR over 1–3 years were obtained from 8991 
subjects, 8017 subjects, and 7787 subjects, respectively. 
Subjects with decrease in percentage change in eGFR of 
more than 40% over 1–3 years were 319 subjects (0.67%), 
338 subjects (0.78%), and 601 subjects (1.43%), respec-
tively, in the high-eGFR group, and 70 subjects (0.78%), 59 
subjects (0.74%), and 55 subjects (0.71%), respectively, in 
the low-eGFR group.
The relationships between percentage change in eGFR 
and risk of ESRD were evaluated. In the high-eGFR group, 
the risk of ESRD tended to be high with decreases in per-
centage change in eGFR of more than 30% over 2 or 3 years 
PPV (%)
=
sensitivity × prevalence × 100
sensitivity × prevalence + (1 − prevalence) × (1 − specificity)
.
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(Fig. 10). In the low-eGFR group, the risk of ESRD also 
tended to be high with decreases in percentage change in 
eGFR of more than 20% over 2 years and of more than 30% 
over 3 years (Fig. 11). Both the high- and low-eGFR groups 
did not show any correlation between the decrease in per-
centage change in eGFR over 1 year and increased risk of 
ESRD. PPV was the highest at the percentage change in 
eGFR of 30% in the high-eGFR group, and high at the per-
centage changes in eGFR of 30% and 40% in the low-eGFR 
group (Fig. 12).
Table 4  Baseline characteristics
Mean ± standard deviation and number of cases (%) are shown
BMI body mass index, SBP systolic blood pressure, eGFR estimated glomerular filtration rate, ESRD end-
stage renal disease
All High-eGFR group Low-eGFR group
N (%) 69,238 58,292 (84.2) 10,946 (15.8)
Male (%) 29,744 (43.0) 25,958 (44.5) 3786 (34.6)
Age (years) 55.6 ± 14.7 53.19 ± 14.2 68.39 ± 10.2
BMI (kg/m2) 24.1 ± 3.4 24.05 ± 3.4 24.27 ± 3.3
SBP (mmHg) 127.8 ± 17.4 126.68 ± 17.2 133.77 ± 17.4
Total cholesterol level (mg/dl) 204.3 ± 35.6 203.1 ± 35.5 210.7 ± 35.9
Urinary protein (%)
 − 66,737 (96.4) 56,543 (97) 10,194 (93.1)
 ± 1671 (2.4) 1224 (2.1) 447 (4.1)
 1 + or more 830 (1.2) 525 (0.9) 305 (2.8)
eGFR (ml/min/1.73 m2) 80.2 ± 21.2 85.4 ± 18.7 52.4 ± 7.0
Percentage change in eGFR over 1 year (%/year) 1.0 ± 19.4 0.8 ± 19.5 2.0 ± 19.0
Percentage change in eGFR over 2 years (%/2 years) 0.5 ± 20.9 0.1 ± 19.5 2.6 ± 27.0
Percentage change in eGFR over 3 years (%/3 years) − 0.3 ± 21.3 − 2.4 ± 20.2 10.7 ± 23.5
ESRD risk (%) 383 (0.55) 186 (0.32) 197 (1.8)
Fig. 9  Distribution of percentage changes in eGFR. Percentage 
changes in eGFR and frequency at each baseline period are shown. 
Percentage changes in eGFR of less than 40% are indicated as − 40%. 
The same applies in other figures below. a High-eGFR group: per-
centage change in eGFR over 1  year: 47,688 subjects, percentage 
change in eGFR over 2 years: 43,381 subjects, percentage change in 
eGFR over 3  years: 42,061 subjects. b Low-eGFR group: percent-
age change in eGFR over 1 year: 8991 subjects, percentage change in 
eGFR over 2 years: 8017 subjects, percentage change in eGFR over 
3 years: 7787 subjects. eGFR estimated glomerular filtration rate




Data In the Olmesartan Reducing Incidence of End-Stage 
Renal Disease in Diabetic kidney disease Trial (ORIENT) 
study, 566 patients with type 2 diabetes accompanied by 
overt nephropathy were followed up for 5 years, to evalu-
ate the effects of olmesartan for reducing the progression of 
nephropathy [34]. These data were analyzed in this study.
Analysis The onset of ESRD (initiation of dialysis) during 
the entire study period was defined as the true endpoint. 
The percentage changes in eGFR for a baseline period 
over 1–3 years were obtained in the same way using the 
above method. Percentage change in eGFR every 10% was 
set as the cutoff level. These were set as the surrogate end-
points. In the evaluation of the surrogate endpoints, the 
surrogate endpoints or true endpoints during the observa-
tional period were analyzed as time-to-event data. First, 
the relationship between the percentage changes in eGFR 
and time-to-true endpoint was evaluated using Cox pro-
portional hazards models. With this Cox proportional haz-
ard model, percentage changes in eGFR were used as con-
tinuous variables, then adjusted for the olmesartan usage 
and baseline characteristics [eGFR, urinary albumin-to-
creatinine ratio (UACR), and country] referring to ear-
lier papers. aHR and 95% CI were obtained using spline 
curves [35]. Next, using the Cox proportional hazard 
model adjusted for the baseline characteristics, the aHRs 
for true endpoints and for surrogate endpoints in the olm-
esartan group were calculated, respectively. After this, the 
bootstrap method was used to calculate the aHR for true 
endpoints and surrogate endpoints in the Cox proportional 
hazard model adjusted for the baseline characteristics, and 
their ratios and 95% CI were obtained [36]:
The closer this aHR is to 1, the more the aHR of the 
true endpoint and that of the surrogate endpoint match.
aHR ratio =
aHR for true endpoint
aHR for surrogate endpoint
.
Fig. 10  Relationships between 
percentage changes in eGFR 
and risk of ESRD in high-
eGFR group. aHR adjusted 
for baseline characteristics 
(gender, age, BMI, systolic 
blood pressure, serum total 
cholesterol level, eGFR, and 
protein level) and 95% CI are 
shown. a Percentage change 
in eGFR over 1 year; − 40% 
aHR 0.70 (95% CI, 0.32–1.54), 
− 30% 0.92 (0.55–1.56),− 20% 
1.22 (0.79–1.88). b Percentage 
change in eGFR over 2 years; 
− 40% 1.43 (0.79–2.57), − 30% 
1.38 (0.84–2.28), − 20% 1.32 
(0.82–2.14). c Percentage 
change in eGFR over 3 years; 
− 40% 1.74 (1.01–2.99), − 30% 
1.49 (0.91–2.43),− 20% 1.27 
(0.80–2.01). ESRD end-stage 
renal disease, BMI body mass 
index, aHR adjusted hazard 
ratio, CI confidence interval
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Results
The characteristics of each group are summarized in 
Table 5. The distributions of percentage changes in eGFR 
are shown in Fig. 13. The olmesartan group consisted of 
282 subjects, and data on percentage changes in eGFR 
over 1–3 years were obtained from 248 subjects, 205 sub-
jects, and 135 subjects, respectively. The control group 
consisted of 284 subjects, and data on percentage changes 
in eGFR over 1–3 years were obtained from 252 subjects, 
193 subjects, and 126 subjects, respectively. Subjects with 
decrease in percentage changes in eGFR of more than 60% 
over 1–3 years were 8 subjects (3.2%), 16 subjects (7.8%), 
and 14 subjects (10.4%), respectively, in the olmesartan 
group, and 6 subjects (2.4%), 13 subjects (6.7%), and 16 
subjects (12.7%), respectively, in the control group. Sub-
jects with decrease in percentage changes in eGFR of more 
than 50% over 1–3 years were 17 subjects (6.9%), 35 sub-
jects (17.1%), and 29 subjects (21.5%), respectively, in 
the olmesartan group, and 13 subjects (5.2%), 32 subjects 
(16.6%), and 29 subjects (23.0%), respectively, in the con-
trol group.
The relationships between percentage changes in eGFR 
and risk of ESRD were evaluated. Although the 95% CI of 
aHR was wide and evaluation was restricted, the greater the 
decrease in percentage changes in eGFR over 1–2 years, the 
higher was the ESRD risk (Fig. 14). No evident correlation 
was found for the percentage changes in eGFR over 3 years.
As for the effects of olmesartan on surrogate endpoints, 
when the decrease in percentage changes in eGFR was more 
than 20% over 1–2 years, there was a tendency for aHR to 
be less than 1 like true endpoints (Fig. 15). However, it was 
more than 1 only when the percentage change in eGFR over 
1 year was 40%. Next, evaluation of the aHR of the true 
endpoint and surrogate endpoint indicated the aHR to be a 
value close to 1 when the percentage changes in eGFR over 
2 years ranged from 20 to 40%. The aHR was closest to 1 at 
40% (Fig. 16).
Fig. 11  Relationships between 
percentage changes in eGFR 
and risk of ESRD in low-
eGFR group. aHR adjusted 
for baseline characteristics 
(gender, age, BMI, systolic 
blood pressure, serum total 
cholesterol level, eGFR, and 
urinary protein level) and 95% 
CI are shown. a Percentage 
change in eGFR over 1 year; 
− 40% aHR 0.74 (0.44–1.25) 
− 30% 0.82 (0.51–1.33), − 20% 
0.90 (0.54–1.48). b Percentage 
change in eGFR over 2 years; 
− 40% 1.57 (0.94–2.62), − 30% 
1.49 (0.92–2.43), − 20% 1.41 
(0.87–2.30). c Percentage 
change in eGFR over 3 years; 
− 40% 1.68 (1.17–2.40), − 30% 
1.38 (1.09–1.76), − 20% 1.12 
(1.00–1.25). ESRD end-stage 
renal disease, BMI body mass 
index, aHR adjusted hazard 
ratio, CI confidence interval
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Discussion
In this study, the data of epidemiological and clinical studies 
were used to evaluate the relationships between true end-
points and surrogate endpoints. To date, epidemiological 
cohort studies on CKD patients in Japan have reported the 
correlation between percentage changes in eGFR and risk 
of ESRD [18, 20]. According to the study on CKD patients 
by Chang et al., decrease in percentage changes in eGFR of 
more than 30% over 2 years correlated with ESRD strongly 
[18]. On the other hand, in a CKD Japan Cohort (Chronic 
Kidney Disease Japan Cohort, CKD-JAC) study, the rela-
tionship between patient distribution and risk of ESRD based 
on percentage changes in eGFR over 1–2 years indicated 30 
or 40% to be the surrogate endpoints [18]. In this study, the 
differences in patient background by age, gender, and the 
causes of CKD were evaluated, and the same correlation 
between percentage changes in eGFR and risk of ESRD was 
seen for each factor [20]. In this study, to investigate subjects 
different from these studies, the data of health examinations 
conducted in Okinawa, Japan, were analyzed.
The relationships between percentage changes in eGFR 
as ESRD surrogate marker and risk of ESRD was investi-
gated. Both the high-eGFR group and low-eGFR group had 
very few subjects showing decrease in percentage changes 
in eGFR of more than 40%. In both groups, the greater 
the decrease in percentage changes in eGFR of more than 
30% over 2–3 years, the higher was the risk of ESRD. 
Fig. 12  Percentage changes in 
eGFR and positive predictive 
value of ESRD. a Percentage 
change in eGFR over 2 years in 
high-eGFR group. b Percentage 
change in eGFR over 3 years in 
high-eGFR group. c Percentage 
change in eGFR over 2 years in 
low-eGFR group. d Percentage 
change in eGFR over 3 years in 
low-eGFR group. PPV positive 
predictive value
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However, the percentage changes in eGFR over 1 year did 
not show such tendency. Coresh et al. reported correlation 
between percentage changes in eGFR over 1–3 years and 
risk of ESRD in both the high-eGFR group and low-eGFR 
group [8]. In this analysis, correlation between percentage 
changes in eGFR over 1 year and risk of ESRD could not 
be demonstrated easily because there were fewer subjects 
showing decrease in percentage changes in eGFR of more 
than 40% than the study by Coresh et al., which may be 
why there were only a few ESRD onsets.
Next, the cutoff levels for percentage changes in 
eGFR over 2 or 3 years were investigated. Studies on 
PPV showed that cutoff levels indicating high PPV were 
30% in the high-eGFR group, and 30 or 40% in the low-
eGFR group. Therefore, based on these findings, percent-
age change in eGFR of 30 or 40% over 2 or 3 years was 
Table 5  Baseline characteristics
Mean ± standard deviation, number of cases (%), median value (first quartile, third quartile) are shown
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HbA1c hemoglobin A1c, 
eGFR estimated glomerular filtration rate, ESRD end-stage renal disease
Olmesartan group Control group
Number of cases 282 284
Age (years) 59.1 ± 8.1 59.2 ± 8.1
Country (Japan/China) 182/100 184/100
Male (%) 199 (70.6) 192 (67.6)
Smoking (%) 72 (25.5) 72 (25.4)
BMI (kg/m2) 25.3 ± 4.2 25.3 ± 3.8
SBP (mmHg) 141.7 ± 17.0 140.8 ± 18.0
DBP (mmHg) 77.8 ± 10.4 77.2 ± 10.6
Albuminuria (mg/mmol) 192.3 (87.1, 339.4) 191.2 (98.4, 352.9)
HbA1c (%) 7.1 ± 1.2 7.1 ± 1.2
eGFR (ml/min/1.73 m2) 37.1 ± 9.6 37.1 ± 10.0
Percentage change in eGFR over 1 year (%/year) − 19.2 ± 18.2 − 18.4 ± 17.0
Percentage change in eGFR over 2 years (%/2 years) − 27.8 ± 22.1 − 28.4 ± 21.1
Percentage change in eGFR over 3 years (%/3 years) − 29.2 ± 22.2 − 32.3 ± 21.7
ESRD risk (%) 74 (26.2) 78 (27.5)
Fig. 13  Distribution of 
percentage changes in eGFR. 
Percentage changes in eGFR 
and frequency at each baseline 
period are shown. Olmesartan 
group: percentage changes in 
eGFR over 1 year: 248 subjects, 
percentage changes in eGFR 
over 2 years: 205 subjects, per-
centage changes in eGFR over 
3 years: 135 subjects. Control 
group: percentage changes in 
eGFR over 1 year: 252 subjects, 
percentage changes in eGFR 
over 2 years: 193 subjects, per-
centage changes in eGFR over 
3 years: 126 subjects
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selected as the candidate surrogate endpoints for both the 
high- and low-eGFR groups in this analysis.
We analyzed the data of the ORIENT study which tar-
geted progressive DKD. In one study, meta-analysis was 
conducted on the relation between true endpoints and sur-
rogate endpoints from 37 randomized trials, and only the 
relationships between the risk of ESRD and percentage 
changes in eGFR over 1 year were investigated. Compared to 
percentage changes in eGFR of 0, 30% was HR 9.6 (95% CI 
7.3–12.6) and 40% was HR 20.3 (95% CI 14.1–29.3). Cor-
relation was found between percentage changes in eGFR and 
risk of ESRD [10]. In this study, the relationships between 
percentage changes in eGFR and risk of ESRD were inves-
tigated. For both percentage changes in eGFR over 1 and 
2 years, the greater the decrease in the percentage changes 
in eGFR, the greater was the tendency toward high risk of 
ESRD. However, this relationship was not seen for percent-
age changes in eGFR over 3 years. One reason why cor-
relation between percentage changes in eGFR over 3 years 
and risk of ESRD was not easily seen in this study may 
be because percentage changes in eGFR over 3 years were 
observed only in a few cases, and as a result, the relation-
ship between percentage changes in eGFR over 3 years and 
risk of ESRD could not be observed accurately. In addition, 
given that this outcome differed from the data of OGHMA, it 
suggests that the appropriate baseline period for percentage 
changes in eGFR differs according to the subject.
Next, the treatment effects were studied. It was found that 
the aHR of ESRD was less than 1 for percentage changes 
in eGFR of 20–30% over 1 year and percentage changes in 
eGFR of 20–50% over 2 years. Of this, percentage changes 
in eGFR over 2 years of 40% showed the closest aHR to the 
true endpoint. In a study conducting the meta-analysis of 
37 randomized trials, the effects of various treatment meth-
ods such as renin–angiotensin–aldosterone system (RAS) 
inhibitor and calcium channel blocker on true endpoints and 
surrogate endpoints were compared [36]. According to this 
study, the evaluation of the HR of RAS inhibitors for true 
endpoints and that for surrogate endpoints indicated it to be 
0.98 (95% CI 0.89–1.07) in the case of percentage changes 
in eGFR of 40% over 2 years and 1.08 (95% CI 0.95–1.20) 
in the case of 30%, demonstrating that 40% is closer to the 
true endpoint result than 30%. For this reason, the percent-
age change in eGFR of 40% over 2 years was selected as the 
candidate surrogate endpoint in this analysis.
Fig. 14  Relationships between 
percentage changes in eGFR 
and risk of ESRD. Logarithm 
of aHR adjusted for baseline 
characteristics (use of olm-
esartan, eGFR, UACR, and 
country) and 95% CI are shown. 
A Percentage change in eGFR 
over 1 year; − 50% aHR 26.77 
(95% CI 9.59–74.74), − 40% 
11.95 (4.33–32.97), − 30% 
5.74 (2.05–16.07), − 20% 3.02 
(0.93–9.83). B Percentage 
change in eGFR over 2 years; 
− 50% 288.40 (3.02–27518.50), 
− 40% 154.85 (1.25–19163.07), 
− 30% 109.03 (0.82–14519.39), 
− 20% 9.70 (0.74–127.30). C 
Percentage change in eGFR 
over 3 years; − 30% 1.27 × 1076 
(0-), − 20% 8.87 × 1025 
(0–1.90 × 10138). aHR adjusted 
hazard ratio, Ln(aHR) natural 
logarithm (adjusted hazard 
ratio), UACR urinary albumin-
to-creatinine ratio
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Taking into account the results of the two analyses in 
this study and results of studies conducted to date, all sub-
jects showed correlation between percentage changes in 
eGFR and risk of ESRD, and the greater the decrease in the 
percentage changes in eGFR, the greater was the tendency 
towards high risk of ESRD. It has been reported that short-
term changes in eGFR during the administration of RAS 
inhibitors are not associated with long-term renal failure 
[37]. The baseline period of 1 year cannot be said to be 
appropriate for observing renal protective effects and the 
onset of side effects [10]. The candidate baseline period was 
2 years in the studies by Coresh et al., Chang et al., and in 
the CKD-JAC study [8, 18, 20]. In our studies, it was 2 or 
3 years in the analysis of the data of OGHMA, and 2 years 
in the analysis conducted in the ORIENT study. The joint 
research group of the US National Kidney Foundation and 
FDA recommends 2 or 3 years [12]. Thus, the candidate 
baseline period of percentage changes in eGFR for surrogate 
endpoints differs according to the subject, and may be 2 or 
3 years.
On the other hand, the candidate cutoff level was 30% in 
the study by Coresh et al., 30% in that by Chang et al., and 
30 or 40% in the CKD-JAC study [8, 18, 20]. In our stud-
ies, it was 30% or 40% in the analysis of the data of health 
examinations conducted in Okinawa, Japan, and 40% in the 
analysis of the ORIENT study. The joint research group of 
the US National Kidney Foundation and FDA recommends 
30 and 40% [37]. The candidate cutoff level of surrogate 
endpoints differs according to the subject, and may be 30 
or 40%. The doubling of the serum creatinine level used 
as the conventional ESRD surrogate endpoint is equivalent 
to 53% decrease in eGFR, when converted to percentage 
change in eGFR based on the eGFR estimation equation 
of the Japanese Society of Nephrology. Moreover, the per-
centage changes in eGFR of 30 and 40% were 1.4 times 
and 1.6 times the respective serum creatinine levels. In the 
study by Coresh et al., comparison of the 57% percentage 
change in eGFR (which is equivalent to the doubling of the 
serum creatinine levels used in the US) and 30% indicated 
that there were only a few subjects with decrease in per-
centage change in eGFR of more than 57% [8]. Here, there 
are two percentage changes in eGFR that are equivalent to 
the doubling of the serum creatinine levels, 53 and 57%, 
due to the mathematical differences between the eGFR esti-
mation equation of the Japanese Society of Nephrology for 
Japanese and CKD Epidemiology Collaboration (CKD-EPI) 
equation used in Europe and the US. In this study, subjects 
with decrease in percentage changes in eGFR of more than 
Fig. 15  Effects of olmesartan on endpoints. aHR adjusted for baseline 
characteristics (eGFR, UACR, and country) and 95% CI are shown. A 
Percentage changes in eGFR over 1 year; − 50% aHR 0.97 (95% CI 
0.58–1.63), −  40% 1.2 (0.79–1.82), −  30% 0.97 (0.7–1.35), −  20% 
0.99 (0.77–1.28), − 10% 1 (0.82–1.23), 0% 1 (0.83–1.2). B Percent-
age changes in eGFR over 2 years; − 50% 0.91 (0.65–1.28), − 40% 
0.95 (0.72–1.26), −  30% 0.94 (0.73–1.21), −  20% 0.96 (0.77–1.2), 
− 10% 1.04 (0.86–1.28), 0% 1.01 (0.83–1.22). C Percentage changes 
in eGFR over 3 years; − 50% 0.95 (0.67–1.33), − 40% 0.98 (0.74–
1.3), − 30% 0.97 (0.75–1.25), − 20% 0.99 (0.79–1.23), − 10% 1.06 
(0.87–1.3), 0% 1.03 (0.85–1.24). True endpoint; 0.88 (0.68–1.14). 
aHR adjusted hazard ratio, True true endpoint throughout study 
period, UACR urinary albumin-to-creatinine ratio
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50% showed a tendency for greater risks of ESRD compared 
to those with 30 or 40%, but subjects with more than 50% 
were rare. The faster the decrease in the percentage changes 
in eGFR, the greater was the risk of ESRD, but the fewer 
was the number of such subjects. In a sample size estima-
tion simulation study, comparison of the sample sizes with 
percentage changes in eGFR of 30 or 40% as the surrogate 
endpoint and with 57% as the surrogate endpoint showed the 
sample size of 30 or 40% to be smaller than the samples size 
of 57% by more than 20% [11].
Candidate surrogate endpoints obtained in this study 
showed varied baseline periods and cutoff levels. Given 
that the baseline period and cutoff level of the appropriate 
percentage changes in eGFR may differ according to the 
subject, there is a need to evaluate various subjects and treat-
ment methods when designing a study, and the need to set 
appropriate surrogate endpoints. Since this study was mostly 
based on the data of health examinations of healthy persons 
and on the retrospective analysis of relatively small-scale 
RCT, it is not clear if the results obtained in this study can 
broadly be applied to CKD patients in Japan. In addition, 
given that the percentage changes in eGFR are calculated 
from serum creatinine levels, they are affected by muscle 
mass, nutritional state, and creatinine excretion amount, 
which may cause eGFR estimation errors [35]. Moreover, 
since errors can occur easily in elderly persons and cases 
with complications such as malnutrition and chronic inflam-
mation, it is advisable to also evaluate renal functions using 
methods based on biomarkers other than serum creatinine. 
If subjects include patients with complications such as car-
diovascular diseases or elderly persons, competing endpoints 
other than ESRD such as death and cardiovascular diseases 
can occur [10]. In such cases, there is a need to evaluate 
composite endpoints taking into account these endpoints.
Conclusion
In this study, the usefulness of the percentage change in 
eGFR as the surrogate endpoint of ESRD was demonstrated. 
The outcome of this study and studies conducted to date sug-
gests that decreases in percentage changes in eGFR of 30 or 
40% over 2 or 3 years may be candidate surrogate endpoints 
for ESRD. Moreover, given that the baseline period and cut-
off level of the appropriate percentage change in eGFR differ 
according to the subject, there is a need to set appropriate 
surrogate endpoints when designing studies.
Fig. 16  Comparison of effects of olmesartan on endpoints. The 
median ratio and 95% CI of the comparison of the effects (aHR) of 
olmesartan on true endpoints and surrogate endpoints are shown. 
Adjusted for baseline characteristics (eGFR, UACR, and country). 
Percentage changes in eGFR over 1  year; −  50% aHR compari-
son 0.96 (95% CI 0.63–1.48), − 40% 0.78 (0.54–1.15), − 30% 0.96 
(0.64–1.44), −  20% 0.95 (0.6–1.44), −  10% 0.95 (0.61–1.47), 0% 
0.95 (0.6–1.48). Percentage changes in eGFR over 2 years; −  50% 
1.03 (0.77–1.38), −  40% 1.0 (0.71–1.34), −  30% 1.01 (0.69–1.41), 
−  20% 0.99 (0.66–1.42), −  10% 0.91 (0.6–1.36), 0% 0.94 (0.62–
1.42). Percentage changes in eGFR over 3 years; − 50% 0.95 (0.75–
1.2), − 40% 0.98 (0.74–1.28), − 30% 0.97 (0.71–1.33), − 20% 0.91 
(0.65–1.28), −  10% 0.95 (0.66–1.36), 0% 0.91 (0.63–1.3). aHR 
adjusted hazard ratio, True true endpoint throughout study period, 
UACR urinary albumin-to-creatinine ratio
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Systematic review
CQ1: What is the appropriate level of decline in GFR 
as a surrogate endpoint of end‑stage renal disease?
Background
In clinical trials on CKD drugs to date, progression to ESRD 
or initiation of renal replacement therapy (dialysis or trans-
plantation) has been widely used as a hard endpoint. How-
ever, reaching these hard endpoints can take considerable 
time depending on the baseline renal function because there 
are only a few events. For this reason, large-scale clinical 
trials with long observational period are required. Further-
more, as renal replacement therapy initiation criteria are 
not standardized, the hard endpoints themselves have been 
called inconsistent. The registration and long-term follow-up 
of a large number of patients to achieve these hard endpoints 
require enormous time and costs, making it difficult for new 
CKD drugs to be developed. To promote the development of 
new CKD drugs, surrogate endpoints allowing fast assess-
ments and highly predictive of progression to ESRD are 
essential. One surrogate endpoint which has already been 
established is the time required for the doubling of serum 
creatinine level. The doubling of the serum creatinine level 
has already been reported in a clinical study conducted in 
the 1970s and has been applied widely since then. However, 
according to the analysis by CKD-EPI, the doubling of the 
serum creatinine level is equivalent to 57% eGFR decline, 
and is considered as a relatively late event. In this study, we 
thus searched literature to determine if even more moderate 
decrease in eGFR can be used as a surrogate endpoint.
Literature search
Literature was searched in Pubmed between January 1970 
and December 2016.
Search terms used were (decline) (glomerular filtration 
rate) (end-stage renal disease) (end-stage kidney disease). 
Nine hundred and thirty-three papers were found using the 
search expressions “(glomerular filtration rate) AND [(end-
stage renal disease) OR (end-stage kidney disease)] AND 
(decline)”. Titles and abstracts were first reviewed to select 
applicable articles, these were then reviewed a second time 
(the entire paper was reviewed), and a total of nine papers 
met this CQ.
Details of search expressions
• (“glomerular filtration rate”[MeSH Terms] OR 
(“glomerular”[All Fields] AND “filtration”[All Fields] 
AND “rate”[All Fields]) OR “glomerular filtration 
rate”[All Fields]) AND ((“kidney failure, chronic”[MeSH 
Terms] OR (“kidney”[All Fields] AND “failure”[All 
Fields] AND “chronic”[All Fields]) OR “chronic kid-
ney failure”[All Fields] OR (“end”[All Fields] AND 
“stage”[All Fields] AND “renal”[All Fields] AND 
“disease”[All Fields]) OR “end-stage renal disease”[All 
Fields]) OR (“kidney failure, chronic”[MeSH Terms] OR 
(“kidney”[All Fields] AND “failure”[All Fields] AND 
“chronic” [All Fields]) OR “chronic kidney failure”[All 
Fields] OR (“end”[All Fields] AND “stage”[All 
Fields] AND “kidney”[All Fields] AND “disease”[All 
Fields]) OR “end-stage kidney disease” [All Fields])) 
AND decline[All Fields] AND (“1970/01/01”[PDAT]: 
“2016/12/31”[PDAT]).
Discussion
Observational study on Stages 3 and 4 of CKD Meta-anal-
ysis using the data of 35 cohorts and 1,700,000 cases of 
the CKD Prognosis Consortium (CKD-PC), a large-scale 
international epidemiological study composed of several 
Japanese cohorts, indicated the frequency of decrease in 
eGFR of 30 and 40% and HR of ESRD risk for 2- and 3-year 
baseline periods. In patients with a baseline eGFR of less 
than 60 ml/min/1.73 m2 (mean eGFR 48 mL/min/1.73 m2), 
the decrease in eGFR of more than 30% in the 2-year base-
line period was 6.9% (95% CI 6.4–7.4), that of more than 
40% was 3.2% (2.8–3.7), and that of more than 57 was 
0.79% (0.52–1.06). Compared to the decrease in eGFR of 
0%, the HR of ESRD risk over 2  years was 5.4 (95% CI 
4.5–6.4) for 30% decrease in eGFR, 10.2 (8.2–12.7) for 40% 
decrease, and 32.1 (22.3–46.3) for 57% decrease. On the 
other hand, the decrease in eGFR of more than 30% in the 
3-year baseline period was 9.5% (95% CI 8.9–10.2), that of 
more than 40 was 4.8% (4.3–5.4), and that of more than 57 
was 1.3% (0.9–1.7). Moreover, the HR of ESRD risk over 
3 years was 5.0 (95% CI 3.9–6.4) for 30% decrease in eGFR, 
10.4 (8.0–13.4) for 40% decrease, and 36.8 (27.3–49.7) for 
57% decrease. In patients with a baseline eGFR of 35 mL/
min/1.73 m2, the risk of progression to ESRD in 10 years 
(revised using covariate and competing risk of death) was 
99% (95% CI 95–100%) for 57% decrease in eGFR over 
2  years, 83% (71–93%) for 40% decrease, 64% (52–77%) 
for 30% decrease, and 18% (15–22%) for 0% decrease [8].
In a meta-analysis of 37 randomized controlled trials on 
CKD patients (9488 subjects, mean age 52 ± 13 years, base-
line eGFR 49.2 ± 24.9 ml/min/1.73 m2), the predictive abil-
ity of already established endpoints (ESRD, eGFR < 15 mL/
min/1.73 m2, doubling of serum creatinine level) was evalu-
ated for patients where 30 or 40% decrease in eGFR was 
observed over 12 months. In the 12-month baseline period, 
eGFR decreased by more than 30 in 16.1% patients, and by 
more than 40 in 7.8% patients. After the 12-month baseline 
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period, further follow-up (median 2 years) revealed that 2661 
patients reached the endpoint. Compared to the decrease in 
eGFR of 0%, the HR for reaching the endpoint was 9.6 (95% 
CI 7.3–12.6) for 30% or more decrease in eGFR, 20.3 (95% 
CI 7.3–12.6) for 40% or more. This relationship was seen 
regardless of the baseline eGFR, proteinuria, underlying dis-
ease, and treatment [10].
In the observational study conducted on Stages 3 and 4 
CKD patients in Japan, the contribution of the following 
terms to the progression to ESRD (initiation of hemodialysis 
or peritoneal dialysis) as an endpoint was reviewed, namely 
baseline eGFR, proteinuria, underlying disease, age, mean 
albumin, hemoglobin, phosphorus, and proteinuria dur-
ing the 2-year baseline period, and percentage decrease in 
eGFR during the 2-year baseline period. During the follow-
up period (4.5 ± 1.3 years), 83 out of the 701 subjects pro-
gressed to ESRD. As for contribution to the progression 
to ESRD, baseline eGFR and proteinuria were the most 
influential factors in the laboratory findings for baseline and 
mean values during the observational period. With every 
10% increase in the percentage decrease in eGFR during 
the 2-year baseline, the HR of the risk of ESRD increased 
exponentially. Compared to the 0 to 10% decrease in 
eGFR, the HR of the progression to ESRD was 38.9 (95% 
CI 5.1–298.1) for the 30 to 40% decrease in eGFR. In the 
laboratory findings for baseline, the 30% decrease in eGFR 
showed the highest HR for progression to ESRD (HR 31.6), 
instead of the mean albumin, hemoglobin, phosphorus, 
and proteinuria. With the Cox proportional hazards model, 
model fitness improved when baseline eGFR, proteinuria, 
albumin, hemoglobin were added [18].
These findings suggest that in CKD Stages 3 and 4 
patients, it may be possible to use 30 or 40% decrease in 
eGFR over 2 or 3 years as a surrogate endpoint by the pre-
diction of the progression to ESRD thereafter.
Observational studies mainly targeting non‑CKD and stages 
1 and 2 of CKD In the atherosclerosis risk in communities 
(ARIC) study, which is a large-scale prospective observa-
tional study on the general population, 9703 subjects who 
could be followed up for a long period of time were investi-
gated with regard to the relationship between progression to 
ESRD (initiation of dialysis and renal transplantation) and 
changes in eGFRcr (creatinine) calculated using the CKD-
EPI equation, eGFRcys (cystatin C) and β2-microglobulin 
reciprocal (1/B2M) over 6 years. The results showed that the 
10 to 30% decrease and more than 30% decrease in eGFRcr, 
eGFRcys, and 1/B2M over 6 years are useful for predict-
ing the risks of progression to ESRD later. HR was 2.6 for 
10 to 30% decrease in eGFRcr, 20.0 for a decrease of more 
than 30%; 3.0 for 10 to 30% decrease in eGFRcys, 16.7 for 
a decrease of more than 30%; 4.0 for 10 to 30% decrease in 
1/B2M, and 22.5 for a decrease of more than 30%. When 
the mean values of the three terms decreased by more than 
30%, risks of ESRD were even higher than eGFRcr alone 
(HR 32.0) [32].
Investigations on the changes in renal functions in shorter 
time than 2 years and progression to ESRD have also been 
reported. Of the CKD Stages 1–4 patients (86% above Stages 
1 and 2) above 18 years old registered with the Alberta Kid-
ney Disease Network, 598,397 subjects whose eGFR was 
measured twice in 6 months–1 year were investigated, and 
adjustments were carried out in the HR using the first avail-
able eGFR. Compared to the group with no change in eGFR, 
the group with more than 25% decrease in eGFR showed 
increase in the HR of ESRD by 5.1 times (95% CI 4.6–5.7). 
However, when HR was adjusted with the last eGFR at base-
line period and covariate, the HR of ESRD did not increase 
in the group with more than 25% decrease in eGFR. It 
has been concluded that change in eGFR (more than 25% 
decrease in eGFR) should be used for predicting risks of 
ESRD based on the measurement of serum creatinine level 
more than twice after at least more than 1 year [31].
Furthermore, a follow-up study was conducted on 161 
subjects with type 1 DM with proteinuria and eGFR ≧ 60 ml/
min/1.73 m2 (CKD Stages 1 and 2) for 5–18 years to inves-
tigate the changes in eGFR and risks of ESRD using serum 
creatinine levels measured for 5 times continuously, the 
tendency for decrease in GFR for 5 ml/min/1.73 m2/year 
in 5 years after the first baseline is able to predict progres-
sion to ESRD after that than glycosylated hemoglobin, blood 
pressure, and urine albumin/gCr ratio [38].
In non-CKD or CKD Stage 1 or 2 patients, decrease in 
eGFR over a long period such as 5 or 6 years may be able to 
predict progression to ESRD. These reports suggest that it 
is difficult to define the observational period and percentage 
change in eGFR, and set the surrogate endpoint.
Interventional studies Investigations comparing the effects 
of CKD intervention between established endpoints (ESRD, 
eGFR < 15 mL/min/1.73 m2 , doubling of serum creatinine 
levels) and new surrogate endpoints (decrease in eGFR of 
57, 40, 30, 20% over 1–3 years)
Investigations were conducted on the 3228 adult 
patients with type 2 diabetic nephropathy (RENAAL mean 
Cr 1.9 mg/dl, mean eGFR 41.4 ml/min/1.73 m2, IDNT 
mean Cr 1.7 mg/dl, mean eGFR 50.2 ml/min/1.73 m2) 
who participated in the Reduction in End Points in Non-
insulin-Dependent Diabetes Mellitus with the Angiotensin 
II Antagonist Losartan (RENAAL) study which verified 
the treatment effects of Angiotensin II Receptor Blocker 
(ARB) and Irbesartan Diabetic Nephropathy Trial (IDNT) 
to compare the predictive ability of ESRD composite 
endpoints, namely doubling of serum creatinine levels 
at months 12, 18, 24, and 36 and 57, 40, 30, and 20% 
decreases in eGFR, or eGFR < 15 ml/min/1.73 m2, as well 
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as evaluate the number of patients reaching the endpoints, 
inconsistencies in ARB treatment effects, and statistical 
significance. When 20% decrease in eGFR was used, there 
were many patients who reached the endpoints, and incon-
sistencies in treatment effects decreased; however, statis-
tical significance decreased [39]. ARB treatment effects 
were compared between use of eGFR before the start of 
ARB treatment and use of eGFR 3 months after start as 
the baseline kidney function. ARB treatment effects were 
evaluated as low (decrease in treatment effects) when 
eGFR before start of treatment was used compared to that 
3 months after start. When the decrease in eGFR was less 
than the doubling of the serum creatinine level, the statis-
tical power of clinical studies did not improve due to the 
reduction of treatment effects, even though inconsistencies 
in treatment effects decreased. The reduction of treatment 
effects is thought to be partially due to the acute effects of 
ARB on eGFR. The Discussion section of this paper states 
that when more moderate decrease in eGFR (namely 20, 
30, 40%) are used as surrogate endpoints in clinical stud-
ies, there is a need to take into account temporary decrease 
in GFR due to the reduction of glomerular perfusion as a 
result of ARB treatment intervention, and set the run-in 
period after treatment instead of setting the start of the 
evaluation of GFR decrease immediately after the start 
of treatment.
Inker et al. [40] conducted a meta-analysis of 37 rand-
omized controlled trials on CKD patients (9488 subjects) 
where they analyzed five treatment interventions (RAS 
inhibition versus control, RAS inhibition versus calcium 
antagonist, aggressive blood pressure management, pro-
tein-restricted diet, immunosuppressive therapy) and CKD 
progression, and evaluated surrogate endpoints 20, 30, 40, 
and 57% decreases in eGFR during the baseline periods of 
12, 18, and 24 months by their predictive ability for already 
established endpoints (ESRD, eGFR < 15 mL/min/1.73 m2, 
doubling of serum creatinine levels). Except for protein-
restricted diet intervention for which strong treatment effects 
were observed, reduction of treatment effects was seen for 
surrogate endpoints. The HR (95% CI) of the respective sur-
rogate endpoints and established endpoints of the five treat-
ment interventions was between 0.91 (0.64–1.43) and 1.12 
(0.89–1.40) in respect to the 40% decrease in eGFR, and 
between 0.88 (0.63–1.39) and 1.15 (0.88–1.54) in respect to 
the 30% decrease in eGFR. Thus, it was concluded that the 
30 or 40% decrease in eGFR can be used as surrogate end-
points, but the use of 40% decrease is supported over 30% 
decrease [40]. In the “Discussion” section of this paper, rea-
sons for the changes in HR observed when decrease in eGFR 
is used as an endpoint include decrease in eGFR (negative 
acute effects) by RAS inhibition, aggressive blood pressure 
management, protein-restricted diet, allometric effects of 
treatment intervention on decrease in eGFR, and influence 
of protein-restricted diet intervention on the production of 
creatinine.
Furthermore, simulation studies reviewing the risks of 
type 1 error (false positive) and sample sizes when decrease 
in eGFR is used as a surrogate endpoint have been reported. 
Although the use of endpoints based on the 30 or 40% 
decrease in eGFR is an appropriate strategy for reducing 
sample size in specific circumstances, the risks of type 1 
error increase when there are acute effects, especially when 
eGFR decreases by 30%. It was concluded that use of these 
endpoints must be decided after evaluating the anticipated 
effects (decrease in sample size, improvement of statisti-
cally detection ability) under specific clinical study condi-
tions [11].
From the results of these interventional studies and simu-
lation studies, when the effects of intervention for CKD are 
evaluated using surrogate endpoints (30 or 40% decrease in 
eGFR over 2 or 3 years), in intervention which may lead to 
temporary decrease in eGFR, it was concluded that there is a 
need to carefully set surrogate endpoints by setting a certain 
run-in period after treatment, and to evaluate the use of 30 
or 40% percentage decrease in eGFR, instead of setting the 
start of evaluation immediately after the start of treatment.
Conclusion
In CKD Stages 3 and 4 patients, the 30 or 40% decrease in 
eGFR over 2 or 3 years may be useful surrogate endpoints 
of progression to ESRD. Given that the appropriate obser-
vational period and percentage decrease in eGFR may differ 
according to the research subject, there is a need to set surro-
gate endpoints according to the research subject. When using 
surrogate endpoints for the evaluation of intervention which 
may cause temporary decrease in eGFR, there is a need to 
carefully set the start time of the observational period and 
select the percentage decrease in eGFR.
CQ2: Is decrease in albuminuria or proteinuria 
an appropriate surrogate endpoint for replacing 
prevention of progression to ESRD?
Background
Albuminuria/proteinuria is an independent risk factor of 
ESRD [41]. In addition, in interventional studies, changes 
in albuminuria/proteinuria due to treatment have been 
reported to be also associated with outcomes such as ESRD, 
doubling of serum creatinine levels, and death [42–46]. 
Consequently, there are reports recommending use of the 
decrease in albuminuria/proteinuria as the surrogate end-
point in interventional studies [47, 48]. On the other hand, 
there are reports concluding that it is an inappropriate sur-
rogate endpoint [49], and reports which state that although 
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there exists sufficient evidence for concluding that decrease 
in proteinuria is a useful surrogate endpoint only for diabetic 
nephropathy and only when RA inhibitor is used in CKDs 
other than diabetic nephropathy [50], indicating a division of 
opinions. Thus, in this CQ, we investigated if the decrease in 
albuminuria/proteinuria is an appropriate surrogate endpoint 
for replacing the prevention of progression to ESRD.
Literature search
Literature was searched in Pubmed between January 1970 
and September 2016. Search terms used were [(proteinuria) 
OR albuminuria)] AND [(kidney failure) OR renal failure]. 
Eight hundred and sixty-three papers were found using the 
following search expressions, and their titles and abstracts 
were first reviewed. Applicable articles were selected and 
reviewed a second time (the entire paper was reviewed). By 
adding some hand search, a total of 10 papers meeting this 
CQ were selected.
((“renal insufficiency”[MeSH Terms] OR (“renal”[All 
Fields] AND “insufficiency”[All Fields]) OR “renal 
insufficiency”[All Fields] OR (“kidney”[All Fields] AND 
“failure”[All Fields]) OR “kidney failure”[All Fields]) 
OR (“renal insufficiency”[MeSH Terms] OR (“renal”[All 
Fields] AND “insufficiency”[All Fields]) OR “renal 
insufficiency”[All Fields] OR (“renal”[All Fields] AND 
“failure”[All Fields]) OR “renal failure”[All Fields])) AND 
((“proteinuria”[MeSH Terms] OR “proteinuria”[All Fields]) 
OR (“albuminuria”[MeSH Terms] OR “albuminuria”[All 
Fields])) AND ((Meta-Analysis[ptyp] OR Rand-
omized Controlled Trial[ptyp] OR systematic[sb]) AND 
(“0001/01/01”[PDAT]: “2016/09/31”[PDAT])).
Discussion
As evidence of this CQ, albuminuria/proteinuria at baseline 
and at the end of the study was measured, and six RCT arti-
cles [42–44, 51–53] and four meta-analysis articles [45, 46, 
54, 55] using ESRD as the endpoint were adopted.
In the RENAAL study verifying the renal protection 
effects of Losartan on patients with diabetic nephropathy 
and overt proteinuria, the relationship between changes in 
albuminuria 6 months after the start of treatment based on 
baseline and ESRD risk was evaluated [42]. Albuminuria 
decreased 28% in the Losartan group based on baseline, 
and increased 4% in the placebo group. Given that ESRD 
risk decreased 45% with every decrease in albuminuria of 
50%, the relative risk of albuminuria reduction effects and 
onset of ESRD showed a more or less linear relationship. 
Likewise, in a post hoc analysis of IDNT study adminis-
tering Irbesartan, Amlodipine, or placebo to patients with 
diabetic nephropathy and overt proteinuria, the relation-
ship between changes in proteinuria 12 months later and 
composite endpoint (doubling of serum creatinine levels, 
or more than 6.0 mg/dL, ESRD) was evaluated [43]. The 
percentage decrease in the mean proteinuria 12 months after 
the start of treatment was 41% in the Irbesartan group, 11% 
in the amlodipine group, and 16% in the placebo group. The 
risks of composite renal endpoints decreased to below half 
each time the proteinuria 12 months after the start of treat-
ment decreased by 50% (HR 0.44; 95% CI 0.40–0.49) [43]. 
In a joint review of the ongoing Telmisartan alone and in 
combination with Ramipril global endpoint trial (ONTAR-
GET) and Telmisartan Randomised AssessmeNt Study 
in ACE iNtolerant subjects with cardiovascular Disease 
(TRANSCEND) conducted on patients with arteriosclerotic 
cardiovascular disease or DM patients with organ damage, 
compared to the groups showing changes in albuminuria 
2 years later of an increase of less than double or decrease 
of up to 50%, the HR of composite endpoints (doubling of 
serum creatinine levels or initiation of dialysis) was 1.4 (95% 
CI 1.11–1.78) in the group showing increase of more than 
100%, and 0.73 (95% CI 0.57–0.95) in the group showing 
decrease of more than 50%. To determine changes in albu-
minuria, renal endpoints were predicted regardless of the 
baseline albuminuria [44]. These randomized controlled 
trials and post hoc analysis results confirmed a relationship 
between the decrease in albuminuria/proteinuria as a result 
of treatment using RA inhibitors for diabetic nephropa-
thy and prevention of progression to ESRD. On the other 
hand, there are four papers reporting systematic review/
meta-analysis reviewing the usefulness of decrease in albu-
minuria/proteinuria as a surrogate endpoint [45, 46, 54, 
55]. In a meta-analysis of 32 randomized controlled trials 
(9008 subjects) evaluating five treatment interventions (RA 
inhibitor, Ca antagonist, intensive depressor therapy, low 
protein diet, and immunosuppressive drug) with renal dis-
ease progression as an outcome, the relationships between 
changes in albuminuria 2.5–13 months later and composite 
endpoints (doubling of serum creatinine level, ESRD, death) 
were investigated [45]. In patients with decreased proteinu-
ria, the risks of reaching the endpoint were low, the total 
HR per decrease in albuminuria of 50% was 0.74 (95% CI 
0.67–0.82). In a meta-analysis of 21 studies (78,342 sub-
jects) investigating the effects of RA inhibitor, intensive 
depressor therapy, dyslipidemia drug, low-protein diet, etc. 
on ESRD, the median observational period of changes in 
albuminuria was 6 months, and the treatment effects for 
albuminuria showed a significant correlation with the treat-
ment effects for ESRD. Each time albuminuria decreased by 
30%, ESRD risks decreased by 23.7% (95% CI 11.4–34.2%) 
[46]. On the other hand, in a meta-analysis of 11 randomized 
controlled trials (830 subjects) investigating the effects of 
RA inhibitor, fish oil, immunosuppressor, and steroid treat-
ment for intensive depressor therapy, dyslipidemia drug, 
low protein diet, etc. on IgA nephropathy, the decrease in 
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proteinuria 9 months after the start of treatment was related 
to the decrease in the risk of composite renal endpoint (dou-
bling of serum creatinine level, ESRD, death), and the HR 
with every decrease in proteinuria of 50% was 0.40 (95% CI 
0.32–0.48). Here, the changes in proteinuria of RA inhibi-
tors and corticosteroids matched the course of treatment 
effects for composite endpoints. It has also been reported 
that when using RA inhibitors and corticosteroids for IgA 
nephropathy, the early decrease in proteinuria is a useful 
surrogate endpoint [54]. Furthermore, in a meta-analysis 
of 27 randomized controlled trials (97,458 subjects) with 
ESRD as the outcome, the validity of the two surrogate end-
points, changes in proteinuria and doubling of serum cre-
atinine levels, was verified using the index, treatment effect 
ratio (TER). TER is the ratio of the treatment effects for 
ESRD and changes in surrogate endpoints. It indicates that 
when TER is close to 1, the treatment effects for ESRD and 
changes in the surrogate endpoint will match. As a result, the 
TER of the doubling of the serum creatinine level obtained 
from 20 RCTs (95,457 subjects, 3850 ESRD events) was 
0.98 (95% CI 0.85–1.14), more or less matching the treat-
ment effects for ESRD. This indicates that the doubling of 
the serum creatinine level is an excellent surrogate endpoint. 
The TER of proteinuria was verified from seven randomized 
controlled trials (17,740 subjects, 173 ESRD events) includ-
ing four randomized controlled trials conducted on subjects 
with diabetic nephropathy accompanied by overt proteinuria. 
Specifically, there were five treatment interventions using 
RA inhibitors, one using dyslipidemia drug and one using 
EDTA chelating agent. As a result, the TER of proteinuria 
was 0.82 (95% CI 0.59–1.16), and changes in proteinuria 
were related to the treatment effects of ESRD. Since little 
data were obtained, it was concluded that there is a limit to 
evidence as a surrogate endpoint [55]. The results of these 
meta-analyses demonstrate that the decrease in albuminu-
ria/proteinuria can be used as a surrogate endpoint for the 
progression of renal disease, not only for RA inhibitor for 
diabetic nephropathy accompanied by overt proteinuria but 
also treatment using RA inhibitor and corticosteroid for 
IgA nephropathy. However, it indicated that compared to 
the doubling of serum creatinine level, evidence is limited.
When decrease in albuminuria/proteinuria is used as 
a surrogate endpoint, is it possible to clearly set the per-
centage increase and observational period? In a post hoc 
analysis of the Olmesartan Reducing Incidence of End-
stage Renal Disease in Diabetic Nephropathy Trial (ORI-
ENT) administering olmesartan or placebo to 566 type 2 
DM patients with overt albuminuria, the mean percentage 
change in proteinuria 24 weeks after the start of treat-
ment was − 19.3% in the olmesartan group and + 5.1% in 
the placebo group. The HR of composite renal endpoints 
(ESRD, doubling of serum creatinine level, death) com-
paring the two groups combined and group with increase 
in proteinuria was 0.54 (95% CI 0.39–0.74) in the group 
with 0–29% decrease, and 0.43 (95% CI 0.31 − 0.61) in the 
group with decrease of more than 30%. The 30% decrease 
in proteinuria 24 weeks after the start of treatment and 
achievement of remaining proteinuria < 1.0 g/gCr were 
related to renal prognosis [51]. In the post hoc analysis 
of the Aliskiren Trial in Type 2 Diabetes Using Cardio-
renal Endpoints (ALTITUDE) administering Aliskiren or 
placebo to 8561 type 2 DM patients with chronic renal 
disease or cardiovascular disease, the median decrease in 
albuminuria 6 months later was 12% in the Aliskiren group 
and 0.0% in the placebo group [52]. When both groups 
are combined, the decrease in albuminuria by more than 
30% 6 months later resulted in 62% decrease in composite 
endpoints (ESRD, serum Cre > 6.0 mg/dL continuing for 
1 month or longer, doubling, death). In both the ORIENT 
and ALTITUDE trials as well as this study, it was not 
possible to decrease composite endpoints even through 
albuminuria was decreased. In all post hoc analyses of 
treatment groups and placebo groups, the decrease in albu-
minuria by more than 30% led to the significant decrease 
in the composite endpoints. The results of these investiga-
tions indicate that significant difference in the percentage 
decrease in albuminuria/proteinuria between the treated 
group and control group is insufficient, and a difference 
of more than 30% is required. The observational period 
of albuminuria/proteinuria varies according to the report 
from 3 months to 2 years. Using the data of 1070 subjects 
of the RENAAL and IDNT trials, a study was conducted 
on the relationships between the variability of albuminuria 
and renal outcome prediction of every patient responding 
to RA inhibitors [53]. Compared to the 0.68 albuminuria 
area under the receiver operating characteristic curve of 
3 months after the start of treatment (95% CI 0.64–0.72), 
that 12 months after was 0.78 (95% CI 0.75–0.82), indi-
cating significantly high renal outcome predictive ability 
(P < 0.001) (Note 1). In addition, it was suggested that 
12–24  months is an appropriate observational period 
for changes in albuminuria/proteinuria; however, there 
is a need to accumulate evidence in the future (Note 
2). Because albuminuria/proteinuria levels often differ 
between spot urine in outpatient visits and first morning 
urine even though they are taken on the same day, ideally 
the measurement time and method, etc. should be stand-
ardized for each study.
Summarizing the above results, RA inhibitor treatment 
for diabetic nephropathy with overt proteinuria and RA 
inhibitor or corticosteroid treatment for IgA nephropathy 
indicated that decrease in albuminuria/proteinuria may be 
a useful surrogate endpoint for replacing prevention of 
progression to ESRD. In particular, in diabetic nephropa-
thy with overt proteinuria, there are many papers showing 
that decrease in albuminuria by more than 50% from the 
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baseline is significant. There are also papers suggesting 
the potentials of using decrease in albuminuria/proteinuria 
of more than 30% from the baseline 12 months after the 
start of treatment can be used as the surrogate endpoint. 
However, evidence is insufficient when eGFR is used as 
an indicator, and also in early CKD. Consequently, at 
this point, it is not appropriate to generally use decrease 
in albuminuria/proteinuria as a surrogate endpoint for 
replacing suppression of progressions to ESRD. There is 
a need to continue accumulating and further investigating 
evidence.
Conclusion
In nephropathy accompanied by proteinuria, the decrease in 
albuminuria/proteinuria is feasible as a surrogate endpoint 
for replacing prevention of progression to ESRD. However, 
there is a lack of evidence when compared to use of eGFR 
as a parameter.
Note 1 This research group investigated the validity of the 
changes in proteinuria as a surrogate endpoint for ESRD 
using the data of OGHMA [56]. Although the findings sug-
gest that changes in proteinuria over 2 years according to the 
test paper method may serve as a significant predictive fac-
tor of ESRD risks even after adjusting with confounders, it 
was not included in this systematic review due to the timing 
of the acceptance of this paper.
Note 2 This CQ is planned for review by the workshop on 
the changes in albuminuria and GFR changes as endpoints 
of early CKD clinical studies jointly hosted by the National 
Kidney Foundation, European Medicines Agency, and US 
Food and Drug Administration on March 15 and 16, 2018.
Summary
Percentage change in eGFR, which has been demonstrated 
to be a potentially useful surrogate endpoint in Europeans 
and Americans for replacing a hard endpoint of ESRD to 
indicate the effectiveness of treatments for CKD, was shown 
to have the same potential usefulness in Japanese.
For both diabetic nephropathy and other CKDs, 30 or 
40% decrease in eGFR over 2 or 3 years may be adopted 
as surrogate endpoints. However, given that the appropriate 
observational period and cutoff value of percentage change 
in eGFR may differ according to the study design (char-
acteristics of subjects, underlying disease, test drug, etc.), 
there is a need to set appropriate surrogate endpoints when 
designing and implementing a study.
The evidence for generally using changes in albuminuria/
proteinuria as the surrogate endpoint of ESRD is not suf-
ficient at this point. Depending on the disease, decrease in 
albuminuria/proteinuria may be used as a surrogate endpoint 
to replace the prevention of progression to ESRD. However, 
there is a need to continue accumulating and evaluating the 
evidence.
The clinical evaluation method for early CKD is also an 
important task. At this point, the evidence for setting this 
is insufficient. But clinical evaluation methods applying 
changes in albuminuria/proteinuria and GFR are drawing 
interests. This would require studies designed for this pur-
pose and the accumulation of evidence.
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